Defense Health Agency Contracting Activity - DHACA
78 open opportunities. Sorted by deadline, soonest first.
DoW Vision, Mentored Clinical Research Award
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training.
Review criteria on fileDoW Hearing Restoration Focused Research Award
Summary: The fiscal year 2026 (FY26) Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) supports promising research that accelerates drug discovery and therapeutic development for hearing restoration after military-relevant auditory system injury.
Review criteria on fileDoW Neurofibromatosis Research Academy – Leadership Award
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Leadership Award (NFRALA) supports visionary, established neurofibromatosis (NF) investigators with documented history of neurofibromatosis funding, publications, strong mentorship and commitment to leadership to serve as…
Review criteria on fileDoW Reconstructive Transplant, Concept Award
Summary: The fiscal year 2026 (FY26) Reconstructive Transplant Research Program (RTRP) Concept Award supports the exploration of highly innovative new concepts or untested theories that address an important problem relevant to reconstructive transplantation. The Concept Award does not support clinical trials .
Review criteria on fileDoW Duchenne Muscular Dystrophy, Idea Development Award
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
Review criteria on fileDoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications.
Review criteria on fileDoW Neurofibromatosis Exploration-Hypothesis Development Award
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research.
Review criteria on fileDoW Neurofibromatosis Investigator-Initiated Research Award
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care.
Review criteria on fileDoW Neurofibromatosis Research Academy – Scholar Award
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Scholar Award (NFRA-SA) supports early-career independent investigators (Scholars) joining the Neurofibromatosis Research Academy to pursue a neurofibromatosis project that may include basic, translational, and/or clinical…
Review criteria on fileDoW Peer Reviewed Medical, Platform Clinical Translation Award
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic…
Review criteria on fileDoW Peer Reviewed Medical, Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and…
Review criteria on fileDoW Neurofibromatosis Synergistic Idea Award
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Synergistic Idea Award (SIA) supports new ideas that represent synergistic approaches to neurofibromatosis (NF) research involving two or three Principal Investigators (PIs).
Review criteria on fileDoW Alzheimer’s Transforming Care Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for individuals with Alzheimer’s disease and Alzheimer’s disease related dementia (AD/ADRD) and…
Review criteria on fileDoW Alzheimer’s Transforming Diagnosis Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Diagnosis Award (TrDA) supports non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis.
Review criteria on fileDoW Alzheimer’s Transforming Research Award
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD).
Review criteria on fileDoW Kidney Cancer, Academy of Kidney Cancer Investigators – Early-Career Scholar Award
Summary: Initially created in fiscal year 2019 (FY19), the Kidney Cancer Research Program (KCRP) Academy of Kidney Cancer Investigators (AKCI) is a unique interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty.
Review criteria on fileDoW Kidney Cancer, Idea Development Award
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS).
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS).
Review criteria on fileDoW Rare Cancers Concept Award
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers.
Review criteria on fileDoW Breast Cancer, Breakthrough Award Level 3
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Review criteria on fileDoW Breast Cancer, Breakthrough Award Level 4
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies.
Review criteria on fileDoW Breast Cancer, Transformative Breast Cancer Consortium Award
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.
Review criteria on fileDoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery.
Review criteria on fileDoW Ovarian Cancer, Clinical Trial Award
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.
Review criteria on fileDoW, Ovarian Cancer, Ovarian Cancer Academy – Early-Career Investigator Award
Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty.
Review criteria on fileDoW, Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award
Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer.
Review criteria on fileDoW, Ovarian Cancer, Investigator-Initiated Research Award
Summary: The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.
Review criteria on fileDoW, Ovarian Cancer, Pilot Award
Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approaches in ovarian cancer, exploring innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.
Review criteria on fileDoW Peer Reviewed Cancer, Idea Award
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research.
Review criteria on fileDoW Peer Reviewed Cancer, Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas.
Review criteria on fileDoW, Peer Reviewed Cancer, Impact Award
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas.
Review criteria on fileDoW Pancreatic Cancer Research Program, Focused Pilot Award
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’…
Review criteria on fileDoW Pancreatic Cancer Research Program, Idea Development Award
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer.
Review criteria on fileDoW Pancreatic Cancer Research Program, Translational Research Partnership Award
Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications.
Review criteria on fileDoW Melanoma Research Program Melanoma Academy Scholar Award
Summary: Supports the addition of independent, early career investigators (Scholars) who are no more than seven years from their initial faculty appointment to the Melanoma Research Program (MRP) Melanoma Academy.
Review criteria on fileDoW Melanoma Research Program Team Science Award
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Team Science Award supports a broad range of hypothesis-driven, multidisciplinary studies that have a short-term goal of advancing the state of the science in melanoma research and/or patient care.
Review criteria on fileDoW Melanoma Research Program Focused Program Award – Rare Melanomas
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas.
Review criteria on fileDoW Melanoma Research Program Idea Award
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Idea Award supports innovative, exploratory, high-risk/potentially high-reward research. Novelty and innovation are expected to be key aspects of the proposed project.
Review criteria on fileDoW Melanoma Research Program Survivorship Research Award
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors,…
Review criteria on fileDoW Traumatic Brain Injury and Psychological Health, Health Services Research Award
Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or…
Review criteria on fileDoW Traumatic Brain Injury and Psychological Health, Translational Research Award
Summary: The Translational Research Award (TRA) intends to accelerate the conversion of scientific findings into impactful clinical applications. The TRA prioritizes innovative approaches over purely iterative or incremental research.
Review criteria on fileDoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including…
Review criteria on fileDoW Military Burn, Discovery Award
Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Discovery Award supports innovative, untested, groundbreaking research that provides new insights and explores early concepts in combat-relevant burn care that provide the foundation for future translational and/or clinical research.
Review criteria on fileDoW Military Burn, Patient-Centered Research Award
Summary: Despite significant research investment in combat-relevant burn care, a disparity exists between newly discovered knowledge in burn care and its implementation into clinical practice across the distributed operational battlespace.
Review criteria on fileDoW Military Burn, Technology/Therapeutic Development Award
Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Technology/Therapeutic Development Award (TTDA) is a burn-focused, product-driven award mechanism intended to provide support for the translation of promising preclinical findings into burn products for clinical application in an austere, resource-limited,…
Review criteria on fileDoW Tick-Borne Disease Therapeutic/Diagnostic Research Award
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care…
Review criteria on fileDoW Autism Idea Development Award
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals.
Review criteria on fileDoW Arthritis Translational Research Award
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions.
Review criteria on fileDoW Tick-Borne Disease Idea Development Award
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Idea Development Award (IDA) is to support conceptually innovative research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other tick-borne…
Review criteria on fileDoW Autism Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism.
Review criteria on fileDoW Autism Career Development Award
Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Career Development Award supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct innovative, high-impact ideas or early-phase, proof-of-principle clinical trials with the potential to have a…
Review criteria on fileDoW Arthritis Clinical Research Award
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy.
Review criteria on fileDoW Bone Marrow Failure, Idea Development Award
Summary: The BMFRP Idea Development Award (IDA) is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP’s vision of understanding and curing BMF diseases.
Review criteria on fileDoW Bone Marrow Failure, Investigator-Initiated Research Award
Summary: Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in bone marrow (BMF) failure research and/or patient care.
Review criteria on fileDoW Bone Marrow Failure, Resource Development Award
Summary: The fiscal year 2026 (FY26) Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) supports the development of a multiomic atlas generated from well-annotated human bone marrow failure (BMF) samples, with omic data derived from marrow specimens.
Review criteria on fileDoW Parkinson’s, Investigator-Initiated Research Award
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research.
Review criteria on fileDoW Parkinson’s, Early Investigator Research Award
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI).
Review criteria on fileDoW Vision, Investigator-Initiated Research Award
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure .
Review criteria on fileShowing 60 of 78. An account shows all of them, ranked by whether you are eligible.
See which Defense Health Agency Contracting Activity - DHACA opportunities you qualify for
An account is free and shows the full announcement, the review criteria reviewers score you against, and whether you are actually eligible — including the windows that close before the deadline does.
No card required.